Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 5—May 2010

Letter

Sorbitol-fermenting Escherichia coli O157, Scotland

Kevin G.J. PollockComments to Author , Mary E. Locking, T. James Beattie, Heather Maxwell, Ian Ramage, David Hughes, Jennifer Cowieson, Lesley Allison, Mary Hanson, and John M. Cowden
Author affiliations: Health Protection Scotland, Glasgow, UK (K.G.J. Pollock, M.E. Locking. J.M. Cowden); Yorkhill Hospital, Glasgow (T.J. Beattie, H. Maxwell, I. Ramage, D. Hughes, J. Cowieson); Scottish E. coli O157/VTEC Reference Laboratory, Edinburgh, UK (L. Allison, M. Hanson)

Main Article

Table

Characteristics of patients infected with non–SF-O157 versus SF-O157 Escherichia coli, Scotland, 2006*

Characteristic
SF-O157, 
n = 8
Non–SF-O157, 
n = 19
p value
Age, y ± SEM 5.4 ± 1.4 5.1 ± 0.9
Sign or symptom, no. (%) patients
Diarrhea 8 19
Bloody diarrhea 6 (75) 14 (74) 0.79
Abdominal pain 6 (75) 13 (68) 0.13
Fever 1 (12) 4 (21) 0.73
Neurologic involvement
2 (25)
4 (21)
0.82
Clinical parameter, mean ± SEM
Anuria, d 11.7 ± 2.7 7.9 ± 1.4 0.20
Leukocyte count, ×109/L 26.4 ± 2.1 36.4 ± 10.1 0.34
C-reactive protein, mg/L 65.6 ± 27.1 93.4 ± 23.1 0.31
Serum albumin, g/L 32.4 ± 7.0 23.2 ± 1.0 0.03
Lactate dehydrogenase, IU/L 2,774 ± 280 2,556 ± 324 0.68
Hospital stay, d
17.9 ± 3.7
16.1 ± 2.9
0.71
Treatment, mean no. sessions ± SEM
Peritoneal dialysis 13.4 ± 2.3 7.4 ± 1.9 0.07
Hemodialysis
20.5 ± 3.5
9.3 ± 1.3
0.01
Outcomes, 1 y follow-up, no. n = 6 n = 19
Full recovery, no. patients 6 17
Clinical sequelae, no. patients 0 2†

*SF, sorbitol-fermenting.
†1 with hypertension, 1 with abdominal pain/vomiting.

Main Article

TOP